A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders

Finnegan, Paula; Ahmad, Kashif; Sadlier, Muriel; Lynch, Maeve

doi:10.1016/j.jdcr.2023.07.007

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finnegan et al conducted a case series on 11 patients diagnosed with malignancy while on biologic therapies [68]. Biologics were prescribed for the treatment of: psoriasis (n = 9), hidradenitis suppurativa (HS) (n = 1), and dual pathology of cutaneous Crohn's disease and HS.…”

Section: Discussionmentioning

confidence: 99%

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Battista,

Gallo,

Martora

et al. 2024

JCM

View full text Add to dashboard Cite

Background: It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and safety of biologic drugs are well-documented in clinical trials and in real-life studies. However, there is limited evidence on the safety of the use of biologic treatments in cancer patients with psoriasis, and the use of this therapeutic class in patients with a pre-existing or concomitant malignancy is still debated. Methods: We have conducted a retrospective observational study of a group of oncology patients with moderate-to-severe psoriasis treated with biologic therapy at the Dermatology Clinic of the University of Naples Federico II, during the period from 2016 to 2024. We included 20 adult patients; in 15 of them the diagnosis of neoplasm preceded the start of treatment biologic, while four of these patients had been diagnosed with cancer during the course of therapy biologics. Results: The most represented neoplasms in our population were breast carcinoma, prostate carcinoma, thyroid carcinoma, and chronic lymphatic leukemia. Anti-IL17 drugs were the most frequently prescribed (47.7%), followed by anti-IL23p19 (36.8%), anti-IL-12/23 (10.5%) and anti-TNF alpha (5.26%). All patients showed improvement of psoriasis after starting the therapy. Conclusions: Our experience supports the effectiveness and safety of biological therapy for psoriasis in patients with a history of cancer or recent onset neoplasia.

show abstract

Section: Discussionmentioning

confidence: 99%

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Battista,

Gallo,

Martora

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Available evidence varies depending on biologic and lymphoma subtype. 3 Nevertheless, a rare cohort of patients will experience both lymphoma and a dermatologic condition that is best managed with biologic therapy. Current guidelines from the Joint American Academy of Dermatology and National Psoriasis Foundation recommend a wait period of 5 years from malignancy diagnosis to use of a biologic therapy.…”

Section: Introductionmentioning

confidence: 99%

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma

Koroneos,

Nicolopoulos,

Dolianitis

2024

JAAD Case Reports

View full text Add to dashboard Cite

A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders

Cited by 2 publications

References 35 publications

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma

Contact Info

Product

Resources

About